期刊
JOURNAL OF MEDICAL VIROLOGY
卷 88, 期 12, 页码 2196-2205出版社
WILEY
DOI: 10.1002/jmv.24578
关键词
herpes simplex virus; antiviral agents; innate immunity; RNA interference (RNAi); anti-herpesvirus drug; interferon
类别
资金
- Academy of Finland [259725, 283192, 250113, 272507, 283072, 255342]
- Sigrid Juselius Foundation
- Drug Research Doctoral Program
- Instrumentarium Foundation
- Finnish Cultural Foundation
- Academy of Finland (AKA) [283192, 259725, 283192, 259725] Funding Source: Academy of Finland (AKA)
Herpes simplex virus (HSV) is a common human pathogen causing severe diseases such as encephalitis, keratitis, and neonatal herpes. There is no vaccine against HSV and the current antiviral chemotherapy fails to treat certain forms of the disease. Here, we evaluated the antiviral activity of enzymatically created small interfering (si)RNA pools against various pathogenic HSV strains as potential candidates for antiviral therapies. Pools of siRNA targeting 0.5-0.8kbp of essential HSV genes UL54, UL29, or UL27 were enzymatically synthesized. Efficacy of inhibition of each siRNA pool was evaluated against multiple clinical isolates and laboratory wild type HSV-1 strains using three cell lines representing host tissues that support HSV-1 replication: epithelial, ocular, and cells that originated from the nervous system. The siRNA pools targeting UL54, UL29, and UL27, as well as their equimolar mixture, inhibited HSV replication, with the pool targeting UL29 having the most prominent antiviral effect. In contrast, the non-specific control siRNA pool did not have such an effect. Moreover, the UL29 pool elicited only a minimal innate immune response in the HSV-infected cells, thus evidencing the safety of its potential clinical use. These results are promising for the development of a topical RNA interference approach for clinical treatment of HSV infection. J. Med. Virol. 88:2196-2205, 2016. (c) 2016 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据